Immuno-Oncology | Specialty

Immunotherapy: What is the Role in Lymphoid Cancers?

July 20th 2016

Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC

July 20th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Pancreatic Cancer: Where to Next?

July 20th 2016

The Future of Pancreatic Cancer

July 20th 2016

Immunotherapy in Pancreatic Cancer

July 20th 2016

Novel Agents in Pancreatic Cancer

July 20th 2016

PARP Inhibitors in Pancreatic Cancer

July 20th 2016

Third-Line Therapy for Pancreatic Cancer

July 20th 2016

Pancreatic Cancer: Updated NCCN Guidelines

July 20th 2016

The NAPOLI-1 Trial in Pancreatic Cancer

July 20th 2016

Pancreatic Cancer Therapeutic Sequencing

July 20th 2016

Therapy for Locally Advanced Pancreatic Cancer

July 20th 2016

Adjuvant Therapy in Locally Advanced Pancreatic Cancer

July 20th 2016

Practical Considerations in Chemotherapy Regimens for Pancreatic Cancer

July 20th 2016

Pancreatic Cancer Upfront Therapy

July 20th 2016

Continued Challenges in Pancreatic Cancer Research

July 20th 2016

Kris Looks Ahead to Lung Cancer Care With Immunotherapy in Spotlight

July 20th 2016

Mark W. Kris, MD, discusses immunotherapy, frontline therapies for nonsquamous non–small cell lung cancer, and advancements in squamous cell carcinoma.

Immunotherapy/Chemo Combinations Show Potential in NSCLC

July 19th 2016

Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.

Avelumab Shows Promise in Early Trial for Advanced Ovarian Cancer

July 19th 2016

Avelumab, a fully human anti–PD-L1 IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with an acceptable toxicity profile.

Expert Enthusiastic About Immunotherapy in SCLC

July 18th 2016

Raffaele Califano, MD, discusses the KEYNOTE-028 and CheckMate-032 trials, the role of PD-L1 as a biomarker in small cell lung cancer, and what is on the horizon for immunotherapies in the landscape of SCLC.